Our proenzyme cancer therapy may have a significant impact on a patient’s survival, says Propanc Biopharma Inc CEO James Nathanielsz
In this interview, SmallCapPower speaks with James Nathanielsz, CEO of Propanc Biopharma Inc, which is a clinical-stage biopharmaceutical company developing a new treatment for metastatic cancer. Propanc Biopharma’s cancer therapy uses proenzymes from the pancreas to halt the ability of cancer cells to spread and recur. This new frontier in cancer therapy is targeted for patients suffering from pancreatic, ovarian and colorectal cancers. According to James Nathanielsz, an added benefit of the Company’s treatment is that it doesn’t cause the typical side effects of standard treatments such as nausea, hair loss or a suppressed immune system.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.